---
schema_version: "secwatch.filing_event.v1"
accession: "0000872589-26-000004"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T06:12:37.790967+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q4 rev $3.88B (+3%), GAAP EPS $7.86; Dupixent +34% to $4.9B

## Summary
- Q4 2025 total revenue $3.884B (+3% YoY); GAAP diluted EPS $7.86 (vs $8.06 Q4 2024); non-GAAP EPS $11.44 (vs $12.07).
- Dupixent global net sales (Sanofi) $4.9B in Q4, +34% YoY; full year $17.8B +26%.
- EYLEA HD U.S. net sales $506M (+66%) but total EYLEA franchise fell 28% to $1.1B on competition and patient transition.
- FDA approved EYLEA HD for RVO and monthly dosing; new vial filler approved; Libtayo approved as first immunotherapy for adjuvant CSCC.
- 2026 guidance: GAAP R&D $6.45-6.68B, non-GAAP gross margin 83-84%; quarterly dividend raised to $0.94/share.

## SEC filing metadata
- accession: 0000872589-26-000004
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/0000872589-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/regn-20260130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000872589-26-000004
- JSON: https://secwatch.observer/filing/0000872589-26-000004.json
- Plain text: https://secwatch.observer/filing/0000872589-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.